Publications by authors named "Michael Emmons"

Claim this Profile
R
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.
Larissa Anastacio Da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S Phadke, Michael F Emmons, Ximo Pechuan-Jorge

Cancer Immunol Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis.
Michael F Emmons, Richard L Bennett, Alberto Riva, Kanchan Gupta, Larissa Anastasio Da Costa Carvalho

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
Sathya Neelature Sriramareddy, Fernanda Faião-Flores, Michael F Emmons, Biswarup Saha, Srikumar Chellappan

Cancer Gene Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
Michael F Emmons, Keiran S M Smalley

J Invest Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.
Chao Zhang, Inna Smalley, Michael F Emmons, Ritin Sharma, Victoria Izumi

J Invest Dermatol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decitabine limits escape from MEK inhibition in uveal melanoma.
Jessica Gonçalves, Michael F Emmons, Fernanda Faião-Flores, Andrew E Aplin, J William Harbour

Pigment Cell Melanoma Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.
Fernanda Faião-Flores, Michael F Emmons, Michael A Durante, Fumi Kinose, Biswarup Saha

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Michael F Emmons, Fernanda Faião-Flores, Ritin Sharma, Ram Thapa, Jane L Messina

Cancer Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.
Michael F Emmons, Nagaraju Anreddy, Javier Cuevas, Kayla Steinberger, Shengyu Yang

Sci Rep· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.
Michael F Emmons, Fernanda Faião-Flores, Keiran S M Smalley

Biochem Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
Anthony W Gebhard, Priyesh Jain, Rajesh R Nair, Michael F Emmons, Raul F Argilagos

Mol Cancer Ther· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.
Joel G Turner, Jana Dawson, Michael F Emmons, Christopher L Cubitt, Michael Kauffman

J Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging strategies for targeting cell adhesion in multiple myeloma.
Rajesh R Nair, Anthony W Gebhard, Michael F Emmons, Lori A Hazlehurst

Adv Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
Michael F Emmons, Anthony W Gebhard, Rajesh R Nair, Rachid Baz, Mark L McLaughlin

Mol Cancer Ther· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Joel G Turner, Douglas C Marchion, Jana L Dawson, Michael F Emmons, Lori A Hazlehurst

Cancer Res· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.
Rajesh R Nair, Michael F Emmons, Anne E Cress, Raul F Argilagos, Kit Lam

Mol Cancer Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Nadine N Bewry, Rajesh R Nair, Michael F Emmons, David Boulware, Javier Pinilla-Ibarz

Mol Cancer Ther· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Lori A Hazlehurst, Raul F Argilagos, Michael Emmons, David Boulware, Craig A Beam

Cancer Res· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis